Home › Funds › SCHOLTZ & COMPANY, LLC › APYX

SCHOLTZ & COMPANY, LLC position in APYX

APYX MEDICAL CORPORATION · Health Care

SCHOLTZ & COMPANY, LLC reported holding 10,000 shares of APYX (APYX MEDICAL CORPORATION) in its Q3 2026 13F filing — a position valued at US$24K, representing 0.01% of its reported portfolio and ranking #44 among its reported holdings. SCHOLTZ & COMPANY, LLC has disclosed APYX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)10.00K sh
Reported value held$24.50K
Portfolio Weight0.01%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SCHOLTZ & COMPANY, LLC's APYX position evolved

SCHOLTZ & COMPANY, LLC first disclosed a stake in APYX in Q3 2023 at 20,000 shares (US$64K). The position peaked in Q4 2025 at 20,000 shares, worth US$70K. Across 12 filings, SCHOLTZ & COMPANY, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 10,000 shares valued at US$24K. Notable position changes include a 50% trim in Q1 2026 (shares rose 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 20.00K $64.00K New
Q4 2023 20.00K $52.00K Hold
Q1 2024 20.00K $27.20K Hold
Q2 2024 20.00K $26.80K Hold
Q3 2024 20.00K $24.80K Hold
Q1 2025 20.00K $27.40K New
Q2 2025 20.00K $45.00K Hold
Q3 2025 20.00K $42.80K Hold
Q4 2025 20.00K $70.00K Hold
Q1 2026 10.00K $36.90K Reduce
Q2 2026 10.00K $44.90K Hold
Q3 2026 10.00K $24.50K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About APYX and 13F data

APYX (APYX MEDICAL CORPORATION) is a Health Care company. 31 other funds we track also report a position in APYX — the largest reported positions include Nantahala Capital Management, LLC (US$14.7M), Archon Capital Management LLC (US$11.9M), Kanen Wealth Management LLC (US$3.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding APYX

All APYX fund holders →

FAQ

How long has SCHOLTZ & COMPANY, LLC held APYX?

SCHOLTZ & COMPANY, LLC has disclosed APYX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

What is SCHOLTZ & COMPANY, LLC's current position in APYX?

As of Q3 2026, SCHOLTZ & COMPANY, LLC holds 10.00K shares of APYX (APYX MEDICAL CORPORATION), valued at $24.50K, representing 0.01% of its reported portfolio and ranking #44.

Has SCHOLTZ & COMPANY, LLC been buying or selling APYX?

In the latest 13F filing (Q3 2026), SCHOLTZ & COMPANY, LLC held unchanged its position in APYX. The position peaked in Q4 2025 at 20.00K shares.

Which other funds hold APYX?

Other major institutional holders of APYX include Nantahala Capital Management, LLC, Archon Capital Management LLC, Kanen Wealth Management LLC, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.